US3876801A - Medicine comprising lysine derivatives - Google Patents

Medicine comprising lysine derivatives Download PDF

Info

Publication number
US3876801A
US3876801A US296583A US29658372A US3876801A US 3876801 A US3876801 A US 3876801A US 296583 A US296583 A US 296583A US 29658372 A US29658372 A US 29658372A US 3876801 A US3876801 A US 3876801A
Authority
US
United States
Prior art keywords
lysine
pantothenate
medicine
treatment
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US296583A
Other languages
English (en)
Inventor
Georges Tixier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of US3876801A publication Critical patent/US3876801A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Definitions

  • the medicme contains lysine pantothcnate 1n sultable [56] References Cited form for re-establishing a normal figure of white blood FOREIGN PATENTS OR APPLICATIONS 87M 1/1961 France 424/319 1 cells in leukopenic patients.
  • the present invention relates to a medicine based on A derivatives of lysine. and especially the pantothenate of Lysine Pammhenme g this essential amino-acid; these derivatives are utilized, Atfimmllcd exclPitfm and h i b h Distilled water Q.S.P. 5 ml accor mg to t e invention. as suita e p armaceutical 1 m 3 ampules per day preparations; they are utilized to cause stimulation of Lysine pantothenate 0.25 g different metabolic mechanisms, particularly of the Excipiem 1 com!
  • the specific physiological activity of the lysine salts, Z0 1 to 2 ampule per d claimed in the present invention, is exemplified by a Th ti product i i n f th b e f group of experimental and clinical observations.
  • lae can be, according to therapeutic needs, reduced up A.
  • the lysine derivatives have no acute or lingering toxtioned quantities. icity.
  • lysine pantothenate The administration of lysine pantothenate at suitable the LD 50 is less than 10 g/kg by oral administration, (loses to patlems 'l leukopeljlla 0f "anous enolo' and gies. causes in a relatively short time, a return to northe LD 50 is less than 8 g/kg by parenteral adminisof the leukocymry ""W' Panamtration.
  • CASE NO. 1 The admi istrt ti in f th i ti 1 s. th e n h l j 't durmg L.
  • Leukocytes Particularly. the administration of lysine pantothenb f after ate to a rat made leukopenic through IIIJCCIIOII of cyclotreatment treatment phosphamide (Endoxan) 40 mg/kg caused an allevia- Numcmion 3000 8000 mm of the poisonous effects. While the leukocyte nu- Polynuclears 33% 59% in rat )f the r fe ence batch remain constant dur Elsl'llphils c t e r I Lymphocytes 57% 34% mg the test. i.e. less than the initial value.
  • treatment treatment I claim: Numeration 3300 7 m 1.
  • a method of increasing the number of leukocytes i in a patient having leukopenia which comprises admin- Lymphocytes 62'); 2.362 istering to said patient, lysine pantothenate in an 3% amount effective to increase the leukocyte numeration of said patient.
  • said lysine pantothenate is administered in a daily dose of 0.2 to 0.4 Numcrauon 6100 7 I00 P olynuclears 53! 6492 bosnwphlls 0 W 8.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
US296583A 1971-10-13 1972-10-11 Medicine comprising lysine derivatives Expired - Lifetime US3876801A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7136804A FR2155890B1 (de) 1971-10-13 1971-10-13

Publications (1)

Publication Number Publication Date
US3876801A true US3876801A (en) 1975-04-08

Family

ID=9084314

Family Applications (1)

Application Number Title Priority Date Filing Date
US296583A Expired - Lifetime US3876801A (en) 1971-10-13 1972-10-11 Medicine comprising lysine derivatives

Country Status (5)

Country Link
US (1) US3876801A (de)
BE (1) BE789856A (de)
DE (1) DE2250032C3 (de)
FR (1) FR2155890B1 (de)
GB (1) GB1381649A (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593044A (en) * 1983-08-05 1986-06-03 Merckle Gmbh Injectable solution for the treatment of inflammations

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0129031A3 (de) * 1983-05-19 1985-10-09 Suntory Limited Antimutagen-Wirkstoff
US4627931A (en) * 1985-01-29 1986-12-09 A. E. Staley Manufacturing Company Method and compositions for hard surface cleaning
DE3744542B4 (de) * 1987-12-30 2004-06-03 Hoerrmann, Wilhelm, Dr. Pharmazeutische Verwendung von L-δ-Hydroxylysin
GB8922701D0 (en) * 1989-10-09 1989-11-22 Leung Lit Hung Compositions and methods for weight reduction
US5635535A (en) * 1996-04-05 1997-06-03 Wagstaff; Robert K. Method for increasing blood glucose levels
GB2314019B (en) * 1996-06-10 2000-03-15 Bio Scient Ltd The use of L-Lysine in the treatment of hair loss

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR87M (de) * 1960-07-29 1961-01-09
FR86M (de) * 1960-07-29 1961-01-09
FR4048M (de) * 1962-04-23 1966-04-04
FR4465M (de) * 1965-06-28 1966-09-26
FR2036045A5 (en) * 1969-03-03 1970-12-24 Tixier Georges Arginine pantothenate prepn

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR87M (de) * 1960-07-29 1961-01-09
FR86M (de) * 1960-07-29 1961-01-09
FR4048M (de) * 1962-04-23 1966-04-04
FR4465M (de) * 1965-06-28 1966-09-26
FR2036045A5 (en) * 1969-03-03 1970-12-24 Tixier Georges Arginine pantothenate prepn

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts 75:88950s (1971), & FR 2036045 A5 (24-12-1970) *
Merck Manual (1972), pp. 300-303. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593044A (en) * 1983-08-05 1986-06-03 Merckle Gmbh Injectable solution for the treatment of inflammations

Also Published As

Publication number Publication date
BE789856A (fr) 1973-02-01
DE2250032A1 (de) 1973-05-10
FR2155890A1 (de) 1973-05-25
FR2155890B1 (de) 1975-04-18
DE2250032B2 (de) 1974-09-19
GB1381649A (en) 1975-01-22
DE2250032C3 (de) 1975-05-22

Similar Documents

Publication Publication Date Title
Tabor et al. Corneal damage due to eye contact with chlorhexidine gluconate
AU723812B2 (en) Medicinal preparation and a method of medicinal action on human organism
US3876801A (en) Medicine comprising lysine derivatives
EP0462075A2 (de) Verwendung von Uridin zur pharmakologischen Behandlung der peripheren Komplikationen bei Diabetes
Fiese Treatment of Disseminated Coccidioidomycosis with Amphotericin B—Report of a Case
US5155096A (en) Method for potentiation of a therapeutic agent
US9943560B2 (en) Medical compositions containing liquorice extracts with synergistic effect
Brown et al. A steady‐state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules
US4990513A (en) Antihypoxic drug and method of its application
US6270756B1 (en) Weight loss induced by alpha interferon and gamma interferon
CN111939158A (zh) 光千金藤碱及其衍生物在制备治疗神经退行性疾病的药物中的应用
CN115813919B (zh) 吲哚-3-丙酮酸或其药用盐在制备治疗乳腺癌药物中的应用
CN108992463A (zh) 一种治疗肺癌的组合物及药物制剂
CN114099493B (zh) 一种抑制胰岛素抵抗的活性化合物及其应用
US4552865A (en) Psychotropic drugs
Chin et al. Use of physostigmine in tricyclic antidepressant poisoning
US3885030A (en) Medicine comprising lysine by-products
Carr et al. Optimal regimens of antituberculous drugs
Welsh Failure of massive doses of vitamin B12 in acute leukaemia
RU1803119C (ru) Способ лечени внематочной беременности
SUTRO et al. Basis and treatment of calcification of tendinocapsular tissues, especially the supraspinatus tendon
BATTERMAN et al. The Therapeutic Effectiveness and Potency of Digilanid in the Treatment of Congestive Heart Failure
CN1175424A (zh) 一种治疗糖尿病的中草药物
Daniels Hospital Formulary: And Compendium of Useful Information
RU1827260C (ru) Способ лечени рассе нного склероза